DDIF 2027 · Who attends
Senior leaders · up to
150
Invited organisations
30
Days · The Savoy
2
In leadership
70%+
The disciplines
Discovery leadership
Chief Scientific Officers, Head of Drug Discovery, R&D Portfolio leads
Translational science
Heads of Translational Medicine, Preclinical Development leads, Biomarker Directors
Regulatory strategy
Global Regulatory Affairs leads, Submission Directors, RA VPs
Early clinical development
First-in-human and Phase I leads, Clinical Pharmacology heads, Medical Directors
Commercial development
BD leads, Licensing heads, Portfolio Strategy Directors
Enabling technology
Informatics, AI/ML in drug discovery, digital research platforms
DDIF 2027 · Invited audience
AstraZeneca
GSK
Roche
Novartis
Sanofi
Bayer
Boehringer Ingelheim
Merck KGaA
Novo Nordisk
Lundbeck
UCB
Galapagos
Argenx
BioNTech
Evotec
Pfizer
Eli Lilly
Merck & Co.
J&J
Bristol Myers Squibb
AbbVie
Gilead
Amgen
Vertex
Regeneron
Moderna
Genentech
Takeda
Daiichi Sankyo
Astellas
Invitations go to the senior leaders of these organisations.
A note on privacy.
This site uses essential cookies to function. We optionally use analytics to understand how the site is used. Nothing is shared. Nothing is sold.